ResMed Inc. (NYSE:RMD) Plans Quarterly Dividend of $0.66

Key Points

• ResMed raised its quarterly dividend 10% to $0.66 per share, payable September 24 to shareholders of record on August 20. The annualized dividend yields approximately 1.3% and is supported by a 22.7% payout ratio.
• ResMed reported quarterly adjusted earnings of $2.95 per share, exceeding estimates, while revenue rose 8.6% year over year to $1.46 billion.
• Despite the earnings beat, the stock fell 7.3% to $206.88 as weaker-than-expected future revenue guidance and reduced analyst price targets raised concerns about moderating growth.

ResMed Inc. (NYSE:RMD - Get Free Report) declared a quarterly dividend on Thursday, August 6th. Investors of record on Thursday, August 20th will be given a dividend of 0.66 per share by the medical equipment provider on Thursday, September 24th. This represents a c) annualized dividend and a yield of 1.3%. The ex-dividend date of this dividend is Thursday, August 20th. This is a 10.0% increase from ResMed's previous quarterly dividend of $0.60.

ResMed has raised its dividend by an average of 0.1%annually over the last three years and has increased its dividend every year for the last 13 years. ResMed has a dividend payout ratio of 22.7% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect ResMed to earn $12.02 per share next year, which means the company should continue to be able to cover its $2.40 annual dividend with an expected future payout ratio of 20.0%.

ResMed Trading Down 7.3%

NYSE:RMD traded down $16.36 during trading hours on Friday, hitting $206.88. The stock had a trading volume of 2,176,155 shares, compared to its average volume of 1,296,391. The business's 50 day moving average is $200.06 and its 200-day moving average is $222.30. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.33 and a current ratio of 3.01. The company has a market cap of $30.01 billion, a price-to-earnings ratio of 20.06, a P/E/G ratio of 1.36 and a beta of 0.76. ResMed has a one year low of $180.26 and a one year high of $293.81.

ResMed (NYSE:RMD - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $2.95 EPS for the quarter, beating analysts' consensus estimates of $2.89 by $0.06. The business had revenue of $1.46 billion during the quarter, compared to analysts' expectations of $1.46 billion. ResMed had a net margin of 27.44% and a return on equity of 25.35%. The firm's quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.55 EPS. Sell-side analysts anticipate that ResMed will post 11.14 EPS for the current fiscal year.

ResMed News Summary

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: ResMed reported fiscal fourth-quarter adjusted earnings of $2.95 per share, above the approximately $2.89–$2.90 consensus estimate and up from $2.55 a year earlier. Revenue rose 8.6% year over year to $1.46 billion, broadly matching expectations. ResMed Q4 Earnings and Revenues Top Estimates
• Positive Sentiment: The company increased its dividend while reporting strong fiscal 2026 results, supporting the investment case for income-focused shareholders. ResMed Reports Strong Q4 Results and Dividend Increase
• Neutral Sentiment: Analyst sentiment remains cautious overall, with the stock carrying an average “Hold” rating despite several Buy recommendations. ResMed Receives Average Hold Rating
• Negative Sentiment: Fiscal 2027 revenue guidance trailed the consensus forecast, raising concerns that growth could moderate and becoming the main reason the stock declined despite the earnings beat. RMD Stock Down Despite Q4 Earnings Beat
• Negative Sentiment: Piper Sandler lowered its price target from $233 to $225 and assigned a Neutral rating, while Wells Fargo cut its target from $225 to $215 and maintained Equal Weight. The revisions reinforce concerns about near-term upside. Analyst Price Target Changes
• Negative Sentiment: Director Peter Farrell sold 8,000 ResMed shares for approximately $1.8 million under a pre-arranged Rule 10b5-1 plan. Because the sale was scheduled in advance, it is a limited signal, but it may add modest selling pressure. SEC Insider Trading Filing

About ResMed

ResMed NYSE: RMD is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed's product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source